Literature DB >> 6965334

Pneumonia during therapy for childhood acute lymphoblastic leukemia.

S E Siegel, M E Nesbit, R Baehner, H Sather, G D Hammond.   

Abstract

The incidence of pneumonia was evaluated in 844 children undergoing initial treatment for acute lymphoblastic leukemia (ALL). A total of 310 episodes occurred in 239 patients followed up for five to 36 months after diagnosis. The peak incidences occurred in the periods 0 to 20 days and 40 to 80 days after the start of antileukemic therapy. Bacterial pneumonias occurred primarily during the first 20 days after diagnosis of ALL. No episode of Pneumocystis carinii pneumonia was noted before 40 days, and the majority of instances occurred 50 to 120 days after diagnosis. In 80% of all episodes, a specific causative organism was not detected. The incidence of P carinii pneumonia was greater in patients receiving intrathecal methotrexate as part of CNS prophylaxis than in those receiving only CNS irradiation. Pneumonia is a frequent event during the therapy of ALL in childhood.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965334     DOI: 10.1001/archpedi.1980.02130130020007

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  8 in total

1.  Current antibiotic usage II: Aminoglycosides, tetracyclines, erythromycin, vancomycin and sulphonamides.

Authors:  S M Merchant; N P Vithlani
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

2.  Pneumonia during the treatment of acute leukaemia.

Authors: 
Journal:  Br Med J       Date:  1980-11-08

Review 3.  Use of cephalosporins in the immunologically compromised patient.

Authors:  A C Newland; H Gaya
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment).

Authors:  Rachael Hough; Ajay Vora
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.

Authors:  Beth A Garvy
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

6.  Serological study of Pneumocystis carinii infection in the absence of immunosuppression.

Authors:  M P Gerrard; O B Eden; B Jameson; A W Craft
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

7.  The trophic life cycle stage of Pneumocystis species induces protective adaptive responses without inflammation-mediated progression to pneumonia.

Authors:  Heather M Evans; Beth A Garvy
Journal:  Med Mycol       Date:  2018-11-01       Impact factor: 4.076

8.  Serious infections during continuing treatment of acute lymphoblastic leukaemia.

Authors:  J Ninane; J M Chessells
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.